Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHAD A LINK

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1750504585
CMS profile
124563
Location
LANSING, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$53,071.09

98 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHAD A LINK

NPI 1750504585 · CMS profile ID 124563

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

LANSING, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750504585?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHAD A LINK, NPI 1750504585, CMS profile ID 124563. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750504585?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CHAD A LINK, NPI 1750504585, CMS profile ID 124563. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750504585?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CHAD A LINK, NPI 1750504585, CMS profile ID 124563, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1750504585?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

98 matching records · $53,071.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 98 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–98 of 98.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $2,525.0005/19/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743474039 CMS
SANOFI-AVENTIS U.S. LLC $1,869.0005/14/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744240061 CMS
PFIZER INC. $13.6105/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743458563 CMS
Lilly USA, LLC $712.5003/24/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728375015 CMS
Actelion Pharmaceuticals US, Inc. $2,340.0003/23/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719072411 CMS
AstraZeneca Pharmaceuticals LP $1,625.0003/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735971867 CMS
AstraZeneca Pharmaceuticals LP $1,175.0003/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736251769 CMS
United Therapeutics Corporation $17.4403/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752462929 CMS
AstraZeneca Pharmaceuticals LP $1,400.0003/12/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735774305 CMS
AstraZeneca Pharmaceuticals LP $3,700.0003/12/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736255969 CMS
Janssen Pharmaceuticals, Inc $14.1803/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719072431 CMS
PFIZER INC. $81.6503/12/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743474067 CMS
AstraZeneca Pharmaceuticals LP $134.5503/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735804805 CMS
AstraZeneca Pharmaceuticals LP $147.0903/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735891629 CMS
AstraZeneca Pharmaceuticals LP $134.5503/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735987037 CMS
AstraZeneca Pharmaceuticals LP $17.2403/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736020015 CMS
AstraZeneca Pharmaceuticals LP $95.6903/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736036669 CMS
AstraZeneca Pharmaceuticals LP $1.1403/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736129149 CMS
E.R. Squibb & Sons, L.L.C. $1,425.0003/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727992259 CMS
Novartis Pharmaceuticals Corporation $11.4703/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725993685 CMS
PFIZER INC. $3,275.0003/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743460467 CMS
Actelion Pharmaceuticals US, Inc. $23.1002/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719072413 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $3.5002/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723104415 CMS
ABIOMED $90.6102/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735166735 CMS
Amarin Pharma Inc. $11.6302/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739829855 CMS
PFIZER INC. $2,500.0002/14/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743459681 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.7502/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720636251 CMS
PFIZER INC. $150.6102/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743461265 CMS
SANOFI-AVENTIS U.S. LLC $9.2102/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744240003 CMS
Amarin Pharma Inc. $20.6502/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739830323 CMS
PFIZER INC. $11.4002/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743470695 CMS
PFIZER INC. $17.7302/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743463927 CMS
Janssen Pharmaceuticals, Inc $13.7501/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719072427 CMS
AstraZeneca Pharmaceuticals LP $36.3601/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736020525 CMS
PFIZER INC. $124.6701/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743806645 CMS
PFIZER INC. $305.8001/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743806647 CMS
PFIZER INC. $327.7701/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743806649 CMS
PFIZER INC. $99.0001/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743806651 CMS
AstraZeneca Pharmaceuticals LP $9.6001/23/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736360217 CMS
Janssen Pharmaceuticals, Inc $13.6301/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719072429 CMS
E.R. Squibb & Sons, L.L.C. $11.9301/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727992235 CMS
PFIZER INC. $1.7001/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743459351 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.4501/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713617493 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $8.5501/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720636257 CMS
Astellas Pharma US Inc $17.6601/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718349835 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $3.9201/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723104411 CMS
Novartis Pharmaceuticals Corporation $14.2001/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725993683 CMS
Amgen Inc. $12.7401/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741374637 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $61,486.37 181
PY2020 $53,071.09 98
PY2021 $44,141.40 100
PY2022 $40,041.84 81
PY2023 $54,017.32 101
PY2024 $39,074.55 88
PY2025 $23,598.79 56

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $61,442.41 72
PY2024 Principal investigator $34,838.96 4
PY2023 Principal investigator $22,206.97 2
PY2022 Principal investigator $15,880.09 3
PY2021 Principal investigator $11,383.00 7
PY2020 Principal investigator $18,211.20 6
PY2019 Principal investigator $19,387.84 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

72 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 12/15/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619964
Principal investigator 1 Boehringer Ingelheim International GmbH $270.00 12/15/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619966
Principal investigator 1 Janssen Research & Development, LLC $3,301.00 12/15/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233655
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 12/10/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619962
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619958
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619960
Principal investigator 1 Janssen Research & Development, LLC $1,860.00 11/21/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233895
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,662.32 11/19/2025 Non-covered Recipient Entity
UM HEALTH SPARROW CLINICAL RESEARCH INSTITUTE
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) No dispute reported 06/30/2026 1190309000
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/18/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994041
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619954
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619956
Principal investigator 1 Janssen Research & Development, LLC $3,137.00 10/22/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233902
Principal investigator 1 Boehringer Ingelheim International GmbH $2,423.00 10/20/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619952
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 10/03/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619950
Principal investigator 1 Boehringer Ingelheim International GmbH $2,758.00 10/02/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619944
Principal investigator 1 Boehringer Ingelheim International GmbH $2,380.00 10/02/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619946
Principal investigator 1 Boehringer Ingelheim International GmbH $1,720.00 10/02/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619948
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619940
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619942
Principal investigator 1 Janssen Research & Development, LLC $2,134.00 09/19/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233360
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619902
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619904
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 08/29/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619920
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 08/29/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619922
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 08/29/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619924
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 08/29/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619926
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 08/29/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619928
Principal investigator 1 Janssen Research & Development, LLC $377.00 08/25/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233460
Principal investigator 1 Janssen Research & Development, LLC $520.00 08/22/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233854
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 08/19/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994039
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 08/17/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619918
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 08/07/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619910
Principal investigator 1 Boehringer Ingelheim International GmbH $189.00 08/07/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619912
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 08/07/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619914
Principal investigator 1 Boehringer Ingelheim International GmbH $2,160.00 08/07/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619916
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619898
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619900
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 07/28/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619930
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 07/28/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619932
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 07/28/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619934
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 07/28/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619936
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 07/28/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619938
Principal investigator 1 Janssen Research & Development, LLC $310.00 07/28/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233593
Principal investigator 1 Boehringer Ingelheim International GmbH $2,828.00 07/25/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619890
Principal investigator 1 Boehringer Ingelheim International GmbH $2,310.00 07/25/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619892
Principal investigator 1 Boehringer Ingelheim International GmbH $1,660.00 07/25/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619894
Principal investigator 1 Boehringer Ingelheim International GmbH $179.00 07/25/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619896
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619906
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619908
Principal investigator 1 Janssen Research & Development, LLC $695.00 06/20/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233708
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619884
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619886
Principal investigator 1 Janssen Research & Development, LLC $520.00 05/23/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233551
Principal investigator 1 Janssen Research & Development, LLC $857.00 05/16/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233667
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619880
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619882
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 04/23/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619888
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619876
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619878
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 03/25/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619868
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 03/25/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619870
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 03/25/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619872
Principal investigator 1 Boehringer Ingelheim International GmbH $11.28 03/25/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619874
Principal investigator 1 Janssen Research & Development, LLC $1,003.00 03/17/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233568
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619862
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619864
Principal investigator 1 Janssen Research & Development, LLC $695.00 02/24/2025 Non-covered Recipient Entity
Sparrow Clinic Rsrch Inst
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175233349
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619858
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619860
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619866
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619854
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Sparrow Clinical Research Institute
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220619856